The launch of Novartis’ Beovu ophthalmology drug could be compromised after a safety warning from doctors over several cases of sight-threatening inflammation of blood vessels.
The market for ophthalmology drugs in Europe just got hotter with the approval of Novartis’ Beovu for neovascular or “wet” age-related macular degeneration, offering a less frequent dosing
